Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allergovit is a subcutaneous allergen immunotherapy (SCIT) product developed by Allergopharma Joachim Ganzer KG. It consists of a hypoallergenic allergoid extract derived from a mixture of six grass pollen species (*Holcus lanatus*, *Dactylis glomerata*, *Lolium perenne*, *Phleum pratense*, *Poa pratensis*, and *Festuca pratensis*) and rye pollen (*Secale cereale*). The allergens are chemically modified with formaldehyde to reduce their IgE-binding capacity (allergenicity) while preserving their ability to induce a protective immune response (immunogenicity). The extract is co-precipitated with aluminium hydroxide, which acts as an adjuvant to provide a depot effect for sustained release. It is indicated for the treatment of IgE-mediated allergic rhinitis, allergic conjunctivitis, and allergic asthma induced by grass and rye pollen, typically administered in a preseasonal regimen to induce immune tolerance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hypoallergenic 6 grass and rye pollen allergoid extract.